Insilico Medicine's Pharma.ai suite is built on proprietary Large Language of Life Models (LLLMs) and a collection of specialized generative AI engines. PandaOmics performs multi-omics target discovery and disease modeling using large-scale biological data. Chemistry42 is a generative chemistry engine that designs novel small molecules optimized for desired properties. Generative Biologics extends this to biologic therapeutics. inClinico applies AI to predict clinical trial success probabilities, while Science42:DORA is an LLM-powered research assistant. The platform is available for enterprise licensing and integrates across the full drug development lifecycle — from target ID through IND-enabling studies and into clinical phases.